Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Maggie's Pearl, LLC
Country
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG
Phase 3
Active, not recruiting
Conditions
Phosphomannomutase 2 Deficiency
Phosphomannomutase 2 Congenital Disorder of Glycosylation
Phosphomannomutase II Congenital Disorder of Glycosylation
Phosphomannomutase II Deficiency
Pmm2-CDG
Interventions
Drug: Placebo
Drug: Epalrestat
Subscribe
First Posted Date
2021-06-14
Last Posted Date
2024-06-03
Lead Sponsor
Maggie's Pearl, LLC
Target Recruit Count
40
Registration Number
NCT04925960
Locations
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy